http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3519426-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_adf225ca4a6bf6190b6a2763410d1ebf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97bd68cb0a98913a5940c708e7ce1679 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43572 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-43568 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate | 2017-10-31^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39a1cd6eb2528cde76dd56ecd4ddfa57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a23361857d709de9bdf35d0c23aa898c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_741f56fa6635a809ad09a5f76c2ac97f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce21d61f7c539b4b96193ec39047141e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec0de4d67863c5426b1e1adca877e4a8 |
| publicationDate | 2019-08-07^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3519426-A1 |
| titleOfInvention | Antimicrobial peptides comprising epsilon lysine residues |
| abstract | The present disclosure relates to a peptide comprising at least five amino acid residues, wherein at least one amino acid residue is modified to an epsilon-lysine, delta-ornithine, gamma-2, 4-diaminobutyric acid, beta-2,3-diaminopropionic acid, with the peptide also comprising at least one non-epsilon lysine, non-delta-ornithine, non-gamma-2, 4-diaminobutyric acid or non-beta-2,3-diaminopropionic acid, and wherein the peptide displays a reduced or no cytotoxicity when compared to an equivalent non-modified peptide. In a preferred embodiment, the modifications are to the melittin or mastoparan B peptides, and comprise the substitution of at least one a-lysine residue for an ε-lysine residue, and the modified peptides display antimicrobial activity. The present disclosure is also directed to pharmaceutical compositions, kits, ophthalmic preparations comprising the modified antimicrobial peptides and use of the modified antimicrobial peptides in methods of inhibiting growth of microorganisms, methods of managing microbial colonization, methods of treating proliferative disease, and methods of treating inflammation. The present disclosure also relates to a method of improving the therapeutic index (safety) of an isolated peptide comprising the aforementioned modification. |
| priorityDate | 2016-11-01^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 196 of 196.